Table of Contents

Economic Evaluation

There are four main reasons a drug doesn't get listed as a general benefit

Price

Provisional listing

Provisional listing (cont'd)

Unstable angina or MI

Improved health / Use of drug

Conclusion

Presentation Author

Andreas Laupacis, MD, MSc, FRCTC, President and Chief Executive Officer, Institute for Clinical Evaluative Sciences (ICES)
( http://www.ices.on.ca )

PMPRB Email

pmprb@pmprb-cepmb.gc.ca

PMPRB Symposium 2002, List of Presentations

http://www.pmprb.com/symposium2002/present-e.html

Email: pmprb@pmprb-cepmb.gc.ca

Home Page: http://www.pmprb.com/symposium2002/present-e.html